RazorSharpDNA 🧬

Intellectual Property (IP) disputes have been part of the CRISPR and Gene Editing landscape from its very beginning. Although previous disputes were mostly between American companies 🧵👇 the $BEAM - $BOLD one is IMO fundamentally different. The fact that an American technology - Base Editing - which was invented and developed in the U.S by Prof. @davidrliu of Harvard and the @broadinstitute, was taken to China to be used in order to develop a parallel pipeline to BEAM’s (AATD) and then returned to the American stock market via a back channel merger is a super negative signal for the entire American BioTech & Pharma ecosystem. IMO this precedent literally means that anyone can simply take a proprietary technology which was developed in the U.S, copy it entirely - for the lack of a better term, only to profit from it without rewarding the actual scientists and entrepreneurs who have spent their lives developing these groundbreaking technologies and bringing them into the clinic. American policy makers need to ask themselves what kind of an incentive a case such as this provides for the next “David Liu” who is sitting right now in his or her lab somewhere in America and for hours upon hours is developing the next novel Genetic delivery platform or the next cure for Cancer? This will have serious implications on the entire industry - far beyond these two companies!